Exposure of Platelets to Dengue Virus and Envelope Protein Domain III Induces Nlrp3 Inflammasome-Dependent Platelet Cell Death and Thrombocytopenia in Mice.
Animals
Biomarkers
Blood Coagulation
Blood Coagulation Tests
Blood Platelets
/ immunology
Cell Death
Dengue Virus
/ physiology
Disease Models, Animal
Disease Susceptibility
Energy Metabolism
Immunophenotyping
Inflammasomes
/ metabolism
Mice
Mice, Knockout
Mitochondria
/ metabolism
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
Platelet Activation
Protein Interaction Domains and Motifs
/ immunology
Severe Dengue
/ complications
Thrombocytopenia
/ blood
Viral Envelope Proteins
/ chemistry
Nlrp3 inflammasome
apoptosis
dengue hemorrhage fever
envelope protein domain III
ferroptosis
necroptosis
platelet
pyroptosis
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2021
2021
Historique:
received:
12
10
2020
accepted:
07
04
2021
entrez:
17
5
2021
pubmed:
18
5
2021
medline:
30
6
2021
Statut:
epublish
Résumé
In tropical and subtropical regions, mosquito-borne dengue virus (DENV) infections can lead to severe dengue, also known as dengue hemorrhage fever, which causes bleeding, thrombocytopenia, and blood plasma leakage and increases mortality. Although DENV-induced platelet cell death was linked to disease severity, the role of responsible viral factors and the elicitation mechanism of abnormal platelet activation and cell death remain unclear. DENV and virion-surface envelope protein domain III (EIII), a cellular binding moiety of the virus particle, highly increase during the viremia stage. Our previous report suggested that exposure to such viremia EIII levels can lead to cell death of endothelial cells, neutrophils, and megakaryocytes. Here we found that both DENV and EIII could induce abnormal platelet activation and predominantly necrotic cell death pyroptosis. Blockages of EIII-induced platelet signaling using the competitive inhibitor chondroitin sulfate B or selective Nlrp3 inflammasome inhibitors OLT1177 and Z-WHED-FMK markedly ameliorated DENV- and EIII-induced thrombocytopenia, platelet activation, and cell death. These results suggest that EIII could be considered as a virulence factor of DENV, and that Nlrp3 inflammasome is a feasible target for developing therapeutic approaches against dengue-induced platelet defects.
Identifiants
pubmed: 33995345
doi: 10.3389/fimmu.2021.616394
pmc: PMC8118162
doi:
Substances chimiques
Biomarkers
0
E-glycoprotein, Dengue virus type 2
0
Inflammasomes
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
Nlrp3 protein, mouse
0
Viral Envelope Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
616394Informations de copyright
Copyright © 2021 Lien, Chan, Sun, Wu, Lin, Lin and Chang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Virulence. 2017 Nov 17;8(8):1719-1731
pubmed: 28622093
Blood. 2013 Jan 3;121(1):95-106
pubmed: 23152543
Front Immunol. 2019 Jul 31;10:1778
pubmed: 31417556
Int J Mol Sci. 2020 Apr 23;21(8):
pubmed: 32340261
J Thromb Haemost. 2013 May;11(5):951-62
pubmed: 23433144
Lancet Infect Dis. 2017 Mar;17(3):e70-e78
pubmed: 28185869
Nat Med. 1997 Aug;3(8):866-71
pubmed: 9256277
Int J Mol Sci. 2020 Mar 31;21(7):
pubmed: 32244433
PLoS Pathog. 2012;8(4):e1002655
pubmed: 22536153
Nature. 2008 May 29;453(7195):672-6
pubmed: 18496526
Front Immunol. 2019 Jun 21;10:1424
pubmed: 31293584
Front Immunol. 2020 Mar 10;11:352
pubmed: 32210961
Thromb Haemost. 2015 May;113(5):1060-70
pubmed: 25740324
Science. 2020 Sep 25;369(6511):1633-1637
pubmed: 32820063
Sci Rep. 2016 Oct 25;6:35868
pubmed: 27779216
Am J Physiol Cell Physiol. 2013 Nov 15;305(10):C1009-10
pubmed: 24005043
Front Immunol. 2020 Mar 25;11:517
pubmed: 32269575
Cell Signal. 2020 Dec;76:109772
pubmed: 32931899
J Infect Dis. 2012 Apr 15;205(8):1321-9
pubmed: 22383677
Front Immunol. 2020 Jun 16;11:1055
pubmed: 32655548
Lancet. 2007 Nov 10;370(9599):1644-52
pubmed: 17993365
J Infect Dis. 2017 Mar 1;215(suppl_2):S89-S95
pubmed: 28403441
Biomed Res Int. 2016;2016:9060143
pubmed: 27403440
Sci Transl Med. 2015 Sep 9;7(304):304ra141
pubmed: 26355030
Cell Res. 2019 May;29(5):347-364
pubmed: 30948788
PLoS One. 2010 Dec 10;5(12):e14289
pubmed: 21170330
Mediators Inflamm. 2015;2015:313842
pubmed: 25999666
Sci Rep. 2018 Feb 9;8(1):2688
pubmed: 29426910
Cell Death Dis. 2019 Feb 12;10(2):128
pubmed: 30755589
Oncotarget. 2018 Jan 30;9(16):12781-12795
pubmed: 29560109
Sci Rep. 2019 Nov 25;9(1):17497
pubmed: 31767905
Front Pharmacol. 2020 Feb 07;11:42
pubmed: 32116717
Toxicol Appl Pharmacol. 2000 Jan 15;162(2):132-41
pubmed: 10637137
Blood. 2010 Dec 2;116(23):5002-9
pubmed: 20699442
Blood. 2007 Apr 15;109(8):3260-9
pubmed: 17192395
Toxins (Basel). 2012 Jul;4(7):568-79
pubmed: 22852069
J Hematol Oncol. 2020 Aug 10;13(1):110
pubmed: 32778143
Int J Mol Sci. 2020 Jul 01;21(13):
pubmed: 32630319
Clin Microbiol Rev. 1998 Jul;11(3):480-96
pubmed: 9665979
Am J Trop Med Hyg. 2008 Jun;78(6):990-8
pubmed: 18541782
Front Immunol. 2020 Oct 09;11:591803
pubmed: 33163006
Front Immunol. 2020 Mar 24;11:479
pubmed: 32265929
J Virol. 2012 Oct;86(20):10961-78
pubmed: 22837196
Cell Commun Signal. 2019 Oct 29;17(1):139
pubmed: 31665027
Lancet Infect Dis. 2017 Mar;17(3):e79-e87
pubmed: 28185870
J Infect Dis. 2002 Sep 15;186(6):743-51
pubmed: 12198607
J Gen Virol. 2013 Oct;94(Pt 10):2215-2220
pubmed: 23884363
J Thromb Haemost. 2010 Feb;8(2):341-50
pubmed: 19840363
Front Immunol. 2021 Feb 25;12:617251
pubmed: 33717109
Sci Rep. 2020 Apr 14;10(1):6294
pubmed: 32286343
Nanomaterials (Basel). 2016 Dec 09;6(12):
pubmed: 28335365
J Immunol. 2015 Sep 15;195(6):2743-53
pubmed: 26259584
J Thromb Haemost. 2007 Nov;5(11):2291-9
pubmed: 17958746
PLoS Pathog. 2019 Apr 22;15(4):e1007625
pubmed: 31009511
Virulence. 2017 Oct 3;8(7):1216-1228
pubmed: 28102766
Int J Mol Sci. 2020 Apr 30;21(9):
pubmed: 32365944
Virulence. 2017 Nov 17;8(8):1492-1493
pubmed: 28829671
Am J Physiol Cell Physiol. 2013 Nov 15;305(10):C1011-20
pubmed: 23986196
Nat Rev Immunol. 2019 Aug;19(8):477-489
pubmed: 31036962
Toxicon. 1998 Aug;36(8):1087-99
pubmed: 9690777
J Immunol. 2014 Aug 15;193(4):1864-72
pubmed: 25015827
J Immunol Methods. 1990 Sep 14;132(2):191-5
pubmed: 2170533
Front Cell Infect Microbiol. 2020 Sep 10;10:489
pubmed: 33014899
PLoS One. 2021 Jul 20;16(7):e0247859
pubmed: 34283836
Exp Cell Res. 1999 Aug 1;250(2):387-400
pubmed: 10413593
Int J Mol Sci. 2020 Sep 25;21(19):
pubmed: 32992921
PLoS One. 2009;4(1):e4167
pubmed: 19132100
Blood. 2013 Nov 14;122(20):3405-14
pubmed: 24009231
Sci Transl Med. 2015 Sep 9;7(304):304ra142
pubmed: 26355031
Front Immunol. 2021 Mar 17;12:618577
pubmed: 33815373
Cell Death Dis. 2011 Jun 09;2:e169
pubmed: 21654827
Front Immunol. 2019 Jul 03;10:1522
pubmed: 31333657
Cell Death Differ. 2018 Mar;25(3):486-541
pubmed: 29362479
Sci Rep. 2019 Apr 29;9(1):6636
pubmed: 31036868
Virulence. 2015;6(5):466-75
pubmed: 25906166
J Infect Dis. 2005 Oct 15;192(8):1465-74
pubmed: 16170766
Front Immunol. 2019 Dec 06;10:2867
pubmed: 31867016
Front Immunol. 2019 Feb 28;10:276
pubmed: 30873162